ALTIMMUNE INC (ALT) Stock Overview
USA - NASDAQ:ALT - US02155H2004 - Common Stock
ALT Key Statistics, Chart & Performance
The current stock price of ALT is 3.78 USD. In the past month the price increased by 7.08%. In the past year, price decreased by -51.48%.
ALT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.01 | 393.01B | ||
| AMGN | AMGEN INC | 13.09 | 153.65B | ||
| GILD | GILEAD SCIENCES INC | 14.74 | 141.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 98.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.97 | 62.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
| ARGX | ARGENX SE - ADR | 79.48 | 45.09B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.84 | 39.75B | ||
| INSM | INSMED INC | N/A | 30.60B | ||
| NTRA | NATERA INC | N/A | 24.86B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 8.9 | 20.89B |
Related stock screener links
About ALT
Company Profile
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm is focused on developing next-generation peptide-based therapeutics. The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The firm also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Company Info
ALTIMMUNE INC
910 Clopper Road, Suite 201S
Gaithersburg MARYLAND 20878 US
CEO: Vipin K. Garg
Employees: 59
Phone: 12406541450
ALTIMMUNE INC / ALT FAQ
What is the stock price of ALTIMMUNE INC today?
The current stock price of ALT is 3.78 USD. The price decreased by -2.33% in the last trading session.
What is the ticker symbol for ALTIMMUNE INC stock?
The exchange symbol of ALTIMMUNE INC is ALT and it is listed on the Nasdaq exchange.
On which exchange is ALT stock listed?
ALT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALTIMMUNE INC stock?
14 analysts have analysed ALT and the average price target is 18.81 USD. This implies a price increase of 397.71% is expected in the next year compared to the current price of 3.78. Check the ALTIMMUNE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALTIMMUNE INC worth?
ALTIMMUNE INC (ALT) has a market capitalization of 333.62M USD. This makes ALT a Small Cap stock.
How many employees does ALTIMMUNE INC have?
ALTIMMUNE INC (ALT) currently has 59 employees.
What are the support and resistance levels for ALTIMMUNE INC (ALT) stock?
ALTIMMUNE INC (ALT) has a support level at 3.44 and a resistance level at 3.84. Check the full technical report for a detailed analysis of ALT support and resistance levels.
Is ALTIMMUNE INC (ALT) expected to grow?
The Revenue of ALTIMMUNE INC (ALT) is expected to grow by 11.2% in the next year. Check the estimates tab for more information on the ALT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALTIMMUNE INC (ALT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALT, evaluating the profitability, health, valuation and growth aspects
- ALTIMMUNE INC (ALT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALTIMMUNE INC (ALT) Sales and EPS estimates to see what analysts future expectations are.
- ALTIMMUNE INC (ALT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALTIMMUNE INC (ALT) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALTIMMUNE INC (ALT) Stock Chart to make your own analysis
- ALTIMMUNE INC (ALT) Latest news and press-releases to stay up to date.
Does ALTIMMUNE INC (ALT) stock pay dividends?
ALT does not pay a dividend.
When does ALTIMMUNE INC (ALT) report earnings?
ALTIMMUNE INC (ALT) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of ALTIMMUNE INC (ALT)?
ALTIMMUNE INC (ALT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
What is the Short Interest ratio of ALTIMMUNE INC (ALT) stock?
The outstanding short interest for ALTIMMUNE INC (ALT) is 30.56% of its float. Check the ownership tab for more information on the ALT short interest.
ALT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALT. When comparing the yearly performance of all stocks, ALT is a bad performer in the overall market: 97.12% of all stocks are doing better.
ALT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ALT. The financial health of ALT is average, but there are quite some concerns on its profitability.
ALT Financial Highlights
Over the last trailing twelve months ALT reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 16.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.1% | ||
| ROE | -54.38% | ||
| Debt/Equity | 0.09 |
ALT Forecast & Estimates
14 analysts have analysed ALT and the average price target is 18.81 USD. This implies a price increase of 397.71% is expected in the next year compared to the current price of 3.78.
For the next year, analysts expect an EPS growth of 15.89% and a revenue growth 11.2% for ALT